Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital

被引:2
|
作者
Subramanian, Charumathi Raghu [1 ,2 ]
Talluri, Swapna [1 ]
Khan, Safi Ullah [1 ,3 ]
Katz, Jeffry A. [4 ]
Georgetson, Michael [5 ]
Sinh, Preetika [6 ]
机构
[1] Robert Packer Hosp, Dept Med, Guthrie Clin, Sayre, PA 18840 USA
[2] Washington Hosp Healthcare Syst, Fremont, CA USA
[3] West Virginia Univ, Dept Med, Morgantown, WV 26506 USA
[4] Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Div Gastroenterol & Liver Dis, Cleveland, OH USA
[5] Guthrie Clin, Div Gastroenterol, Dept Med, Sayre, PA USA
[6] Med Coll Wisconsin, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA
关键词
Fecal microbiota transplant; Clostridium difficile infection; Inflammatory bowel disease; INFLAMMATORY-BOWEL-DISEASE; VANCOMYCIN; GUIDELINES; DIAGNOSIS; PROTOCOL; DIARRHEA; ADULTS; RISK;
D O I
10.14740/gr1275
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Cure rates of Clostridium difficile infection (CDI) with fecal microbiota transplant (FMT) have been promising. However, there is debate regarding success of FMT in patients with comorbidities. Methods: Electronic chart review was done to collect data on patients who underwent FMT from January 2015 to August 2017. Charts were analyzed in November 2018 with a median follow-up of 25.4 months (interquartile range 20 - 31 months). Results: Twenty patients underwent FMT. The primary success rate at our institution was 90% and overall success rate was 100%. Six patients (43%) had FMT failure (two early and four late). Conclusions: This case series is a description of our center's initial experience with FMT for treatment of recurrent CDI. Our high success rate reiterates the efficacy and safety of FMT in this population including patients with comorbidities.
引用
收藏
页码:138 / 145
页数:8
相关论文
共 50 条